home / stock / lnth / lnth news


LNTH News and Press, Lantheus Holdings Inc. From 05/04/23

Stock Information

Company Name: Lantheus Holdings Inc.
Stock Symbol: LNTH
Market: NASDAQ
Website: lantheus.com

Menu

LNTH LNTH Quote LNTH Short LNTH News LNTH Articles LNTH Message Board
Get LNTH Alerts

News, Short Squeeze, Breakout and More Instantly...

LNTH - Lantheus Non-GAAP EPS of $1.47 beats by $0.18, revenue of $300.78M beats by $20.12M

2023-05-04 07:21:18 ET Lantheus press release ( NASDAQ: LNTH ): Q1 Non-GAAP EPS of $1.47 beats by $0.18 . Revenue of $300.78M (+44.0% Y/Y) beats by $20.12M . Q2 Guidance: Revenue of $300M-$310M Adj EPS of $1.25-$1.33 FY23 Outlook: revenue of $1....

LNTH - Lantheus Reports First Quarter 2023 Financial Results

Worldwide revenue of $300.8 million for the first quarter 2023, representing an increase of 44.0% from the prior year period GAAP net loss of $2.8 million for the first quarter 2023, compared to GAAP net income of $43.0 million in the prior year period GAAP fully diluted net loss ...

LNTH - Lantheus Q1 2023 Earnings Preview

2023-05-03 13:43:14 ET Lantheus ( NASDAQ: LNTH ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open. The consensus EPS Estimate is $1.29 (+33.0% Y/Y) and the consensus Revenue Estimate is $280.66M (+34.4% Y/Y). Over the last 2 years, ...

LNTH - Lantheus, POINT Biopharma receive FDA Fast Track status for prostate cancer candidate

2023-04-24 08:39:37 ET For further details see: Lantheus, POINT Biopharma receive FDA Fast Track status for prostate cancer candidate

LNTH - Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹??Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find...

LNTH - Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fig...

LNTH - Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time

BEDFORD, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 4, 2023, to discuss its financial and operating results for the first quarte...

LNTH - ClearBridge Small Cap Strategy Q1 2023 Portfolio Manager Commentary

2023-04-14 04:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperfor...

LNTH - POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH registrational trial, with top line data expected in the second half of 2023 INDIANA...

LNTH - Lantheus promotes internal candidate to President role

2023-03-17 08:48:20 ET Lantheus ( NASDAQ: LNTH ) announced that Paul Blanchfield has been promoted to President and Dan Niedzwiecki has been promoted to Chief Administrative Officer. Paul was instrumental in the successful launch of the company...

Previous 10 Next 10